Glowania H J, Hampl B
Bundeswehrzentralkrankenhaus Koblenz, Dermatol.-Venerol, Abteilung.
Z Hautkr. 1988 Mar 21;63(3):211.
12 patients suffering from hemorrhoidal complaints were treated with hemorrhoidal suppositories containing Proctoparf-bufexamac. Using the HPCL method, we measured the concentrations of bufexamac in the serum after 30, 45 and 60 minutes as well as after 2, 3, 6, 7.5 and 20 hours. Neither bufexamac nor its major metabolite (4-butoxyphenyl acetic acid) could be detected in concentrations above 0.2 micrograms/ml and 0.5 micrograms/ml, respectively. These results prove that the application of Proctoparf suppositories is not associated with any significant systemic absorption of bufexamac.
12名患有痔疮疾病的患者使用了含有丙帕他莫-丁苯羟酸的痔疮栓进行治疗。我们采用高效液相色谱法(HPCL),分别在30、45和60分钟以及2、3、6、7.5和20小时后测定血清中丁苯羟酸的浓度。丁苯羟酸及其主要代谢物(4-丁氧基苯乙酸)的浓度分别未检测到高于0.2微克/毫升和0.5微克/毫升。这些结果证明,丙帕他莫栓的应用与丁苯羟酸的任何显著全身吸收均无关联。